Glomerulonephritis: haematuria, rapidly progressive kidney injury and urgent workup

Clinical scope and immediate priorities

Glomerulonephritis should be suspected when kidney dysfunction accompanies glomerular haematuria, proteinuria, hypertension or systemic inflammatory features. Rapidly progressive disease can cause irreversible kidney loss over days to weeks, so urgent nephrology assessment should not wait for every serology result. Kidney disease changes fluid, electrolyte and medication handling across almost every specialty. Trends are often more informative than a single creatinine or electrolyte result. Volume status, urine findings, nephrotoxic exposures, obstruction, acid-base status and the tempo of change should be considered together, with early specialist escalation when complications become difficult to control.

Recognition and differential diagnosis

Clues include cola-coloured urine, oedema, new hypertension, active urinary sediment and a rising creatinine. Ask about rash, arthritis, sinus or pulmonary symptoms, haemoptysis, recent infection, chronic infection, new medicines and systemic autoimmune disease. Pulmonary haemorrhage with AKI is a medical emergency. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Urinalysis and microscopy can show dysmorphic red cells and casts, while protein quantification helps characterise severity. Check complement and targeted serology such as ANCA, anti-GBM and ANA according to phenotype, plus hepatitis and other infection testing before immunosuppression. Kidney biopsy is usually central when diagnosis is uncertain or disease-specific therapy is contemplated. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Supportive care includes blood-pressure and volume management, avoiding nephrotoxins and treating severe electrolyte complications. Immunosuppression varies substantially by diagnosis; anti-GBM disease, ANCA-associated vasculitis, lupus nephritis and infection-related GN require different strategies. Do not start prolonged empiric immunosuppression without reasonable diagnostic direction unless delay poses immediate threat and specialist care is involved. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Rapid creatinine rise, oliguria, hyperkalaemia, pulmonary haemorrhage, severe hypertension or systemic vasculitis features requires urgent nephrology and sometimes critical-care management. Plasma exchange has selected indications rather than a universal role across all rapidly progressive GN. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Monitor renal function, proteinuria, urinary sediment and treatment toxicity. Infection prophylaxis and vaccination may be needed during immunosuppression.

Common pitfalls and safety checks

Do not dismiss microscopic haematuria when it occurs with proteinuria and renal dysfunction. Normal complement does not exclude serious glomerulonephritis. Serology supports but does not invariably replace biopsy. Pulmonary-renal syndrome requires urgent coordinated care. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Kidney-focused implementation requires deliberate medication reconciliation because dosing, nephrotoxicity and electrolyte effects change as renal function changes. Communicate baseline creatinine or eGFR, recent trend, urine findings, volume assessment and the plan for repeat tests. Pharmacists and primary-care teams are essential for avoiding unsafe combinations after discharge. Patients should know which intercurrent illnesses or medicines warrant earlier review. Access to nephrology and dialysis services differs by region, so early consultation is preferable when trajectory suggests that advanced support may be needed.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.